title: Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
abstract: OBJECTIVE
  The aim of the present study was to investigate the diagnostic and prognostic value of combined (18)F-2-fluorodeoxyglucose positron emission tomography and contrast enhanced X-ray computed tomography (FDG-PET/CT) in women with a suspicion of recurrent ovarian cancer.
  
  
  METHODS
  We retrospectively reviewed 48 patients with a suspicion of recurrent ovarian cancer who were referred to our department for combined FDG-PET/CT.
  
  
  RESULTS
  Median follow-up was 25 months. 38/48 (79%) patients showed pathological findings on PET/CT. 17/48 (35%) of patients died of ovarian cancer. One FDG-PET/CT was false positive and one was false negative, leading to a sensitivity and positive predictive value of 97% and a specificity and negative predictive value of 90%. 33/48 (69%) underwent a change in therapy following FDG-PET/CT. There was a significantly better survival in FDG-PET/CT negative than in positive patients (p=0.04). In the FDG-PET/CT negative group no patients had died of ovarian cancer during follow-up. Remarkably, there was no difference in survival between patients who only had peritoneal metastases on FDG-PET/CT and those who also had extraperitoneal metastases (p=0.71).
  
  
  CONCLUSIONS
  A negative FDG-PET/CT has a high negative predictive value for the presence of disease and, more importantly, is associated with a very good disease-specific survival rate.
authors.affiliation: University Hospital Aachen, Department of Nuclear Medicine, Pauwelsstraße 30, 52074 Aachen, Germany.
authors.forename: Carolin B
authors.initials: CB
authors.lastname: Hebel
authors.affiliation: University Hospital Aachen, Department of Nuclear Medicine, Pauwelsstraße 30, 52074 Aachen, Germany.
authors.forename: Florian F
authors.initials: FF
authors.lastname: Behrendt
authors.affiliation: University Hospital Aachen, Department of Nuclear Medicine, Pauwelsstraße 30, 52074 Aachen, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Heinzel
authors.affiliation: University Hospital Aachen, Department of Nuclear Medicine, Pauwelsstraße 30, 52074 Aachen, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Krohn
authors.affiliation: University Hospital Aachen, Department of Nuclear Medicine, Pauwelsstraße 30, 52074 Aachen, Germany; Maastricht University Medical Center, Department of Nuclear Medicine, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.
authors.forename: Felix M
authors.initials: FM
authors.lastname: Mottaghy
authors.affiliation: University Hospital Aachen, Department of Gynecology and Obstetrics, Pauwelsstraße 30, 52074 Aachen, Germany.
authors.forename: Dirk O
authors.initials: DO
authors.lastname: Bauerschlag
authors.affiliation: University Hospital Aachen, Department of Nuclear Medicine, Pauwelsstraße 30, 52074 Aachen, Germany; Maastricht University Medical Center, Department of Nuclear Medicine, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands. Electronic address: fverburg@ukaachen.de.
authors.forename: Frederik A
authors.initials: FA
authors.lastname: Verburg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D064847:Multimodal Imaging / Q000706:statistics & numerical data; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000401:mortality* / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality*; D049268:Positron-Emission Tomography / Q000706:statistics & numerical data*; D015995:Prevalence; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012189:Retrospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000706:statistics & numerical data*; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: FDG-PET/CT; Ovarian cancer; Prognosis